2024-09-19 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops and manufactures innovative medicines for patients with serious illnesses.

**Performance Analysis:**

1. **Performance vs. S&P 500:** AMGN's cumulative return of 86.05% lags behind the S&P 500 (VOO) which has a cumulative return of 129.06%. This puts AMGN at a -43.01% relative performance compared to the S&P 500. The relative performance is currently at the 42.76th percentile compared to historical data, indicating that AMGN has underperformed compared to the market in the past.

2. **Recent Price Movements:** AMGN's current closing price is $332.02. It is slightly above the 5-day moving average of $331.95, suggesting potential upward momentum. However, it is below the 20-day moving average of $328.99 and the 60-day moving average of $326.02, indicating a slight downward trend over longer periods.

3. **Technical Indicators:**
   - **RSI:** The RSI of 56.63 suggests that the stock is currently in neutral territory, neither overbought nor oversold.
   - **PPO:** The PPO of 0.15 indicates a slight positive momentum, but not a strong signal. 
   - **Delta_Previous_Relative_Divergence:** The positive value of 1.65 suggests a short-term upward trend.
   - **Expected_Return:** The 8.93% expected return based on the current investment represents the maximum expected return over the next 5 years.

4. **Recent Earnings and Outlook:**
   - **Latest Earnings:** The most recent earnings report for the quarter ending 2024-08-07 showed earnings per share (EPS) of $1.39 and revenue of $8.39 billion. This exceeded analysts' expectations of $1.27 EPS and $8.14 billion in revenue. 
   - **Historical Earnings:** Analyzing the past few quarters, AMGN has experienced fluctuations in EPS and revenue. However, the latest earnings beat expectations, indicating a potential positive trend.

**Overall Analysis:**

While AMGN has underperformed compared to the S&P 500 in the past, recent earnings have exceeded expectations, signaling a possible positive turnaround. The stock's RSI and PPO indicate a neutral-to-slightly positive momentum, while the positive Delta_Previous_Relative_Divergence suggests a potential short-term uptrend. The expected return of 8.93% is attractive but needs further evaluation considering the current market conditions.

**Recommendation:**

AMGN presents a mixed picture with both potential opportunities and risks. Further research is recommended to better understand the company's long-term growth prospects, competitive landscape, and potential impact of market volatility. Investors should consider their own risk tolerance and investment goals before making any decisions.